SERES THERAPEUTICS, INC. (NASDAQ:MCRB) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.
On June20, 2017, Seres Therapeutics, Inc. (the Company) held its
Annual Meeting of Stockholders. A total of 32,385,591 shares of
common stock were present in person or represented by proxy at
the meeting, representing approximately 80.2percent of the
Companys outstanding common stock as of the April26, 2017 record
date. The following are the voting results for the proposals
considered and voted upon at the meeting, all of which were
described in the Companys Definitive Proxy Statement filed with
the Securities and Exchange Commission on May1, 2017.
Item 1 Election of two ClassII directors to serve until the 2020
Annual Meeting of Stockholders, and until their respective
successors have been duly elected and qualified.
| NOMINEE | Votes FOR |
VotesWITHHELD |
BrokerNon-Votes |
|||||||||
|
|
25,676,854 | 1,173,511 | 5,535,226 | |||||||||
|
|
25,126,028 | 1,724,337 | 5,535,226 |
Item 2 Ratification of the appointment of PricewaterhouseCoopers
LLP as the Companys independent registered public accounting firm
for the year ending December31, 2017.
Votes FOR |
VotesAGAINST |
VotesABSTAINED |
BrokerNon-Votes |
|||||||||||
| 32,334,687 | 41,675 | 9,229 |
Based on the foregoing votes, Richard N. Kender and Lorence H.
Kim, M.D. were elected as ClassII directors and Item 2 was
approved.
About SERES THERAPEUTICS, INC. (NASDAQ:MCRB)
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases.
